Keratoconjunctivitis sicca associated with administration of etodolac in dogs: 211 cases (1992–2002)

Gia Klauss Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Gia Klauss in
Current site
Google Scholar
PubMed
Close
 DVM, DACVO
,
Elizabeth A. Giuliano Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Elizabeth A. Giuliano in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVO
,
Cecil P. Moore Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Cecil P. Moore in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVO
,
Charles M. Stuhr Animal Eye Clinic, 2 Pimpewaug Rd, Wilton, CT 06897.

Search for other papers by Charles M. Stuhr in
Current site
Google Scholar
PubMed
Close
 DVM, DACVO
,
Stacy L. Martin Fort Dodge Animal Health, 9225 Indian Creek Pkwy # 400, Overland Park, KS 66210.

Search for other papers by Stacy L. Martin in
Current site
Google Scholar
PubMed
Close
 DVM
,
Jeff W. Tyler Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Jeff W. Tyler in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM
,
Kelsie E. Fitzgerald Animal Eye Clinic, 2 Pimpewaug Rd, Wilton, CT 06897.

Search for other papers by Kelsie E. Fitzgerald in
Current site
Google Scholar
PubMed
Close
, and
Debra A. Crawford Fort Dodge Animal Health, 9225 Indian Creek Pkwy # 400, Overland Park, KS 66210.

Search for other papers by Debra A. Crawford in
Current site
Google Scholar
PubMed
Close

Abstract

Objective—To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs.

Design—Retrospective case series.

Sample Population—65 cases obtained from a survey of veterinary ophthalmologists (group A) and 146 cases reported to Fort Dodge Animal Health (group B).

Procedures—Data analyzed included breed, sex, age, weight, dose and duration of etodolac administration, results of Schirmer tear test at the time of diagnosis and last follow-up, treatments, and response to treatments. Groups A and B were analyzed separately by use of forward stepwise logistic regression models developed to predict probability of complete remission or clinical improvement as a function of several variables.

Results—Most dogs developed severe KCS (84 eyes of 50 dogs [group A]; 111 eyes of 62 dogs [group B]). Resolution of KCS occurred in 7 of 65 (A) and 23 of 146 (B) dogs. No response to treatment was observed in 26 of 65 (A) and 27 of 146 (B) dogs. Fifty-one (A) and 52 (B) dogs had records that were sufficiently complete to use in models. In group B, dogs with etodolac treatment intervals < 6 months prior to the onset of KCS were 4.2 times as likely to have remission as were dogs with treatment intervals ≥ 6 months.

Conclusions and Clinical Relevance—Shorter duration of etodolac administration (< 6 months) was associated with improved outcome in 1 population of dogs. Monitoring of tear production should be considered prior to and during administration of etodolac in dogs.

Abstract

Objective—To characterize features and response to treatment of keratoconjunctivitis sicca (KCS) associated with oral administration of etodolac in dogs.

Design—Retrospective case series.

Sample Population—65 cases obtained from a survey of veterinary ophthalmologists (group A) and 146 cases reported to Fort Dodge Animal Health (group B).

Procedures—Data analyzed included breed, sex, age, weight, dose and duration of etodolac administration, results of Schirmer tear test at the time of diagnosis and last follow-up, treatments, and response to treatments. Groups A and B were analyzed separately by use of forward stepwise logistic regression models developed to predict probability of complete remission or clinical improvement as a function of several variables.

Results—Most dogs developed severe KCS (84 eyes of 50 dogs [group A]; 111 eyes of 62 dogs [group B]). Resolution of KCS occurred in 7 of 65 (A) and 23 of 146 (B) dogs. No response to treatment was observed in 26 of 65 (A) and 27 of 146 (B) dogs. Fifty-one (A) and 52 (B) dogs had records that were sufficiently complete to use in models. In group B, dogs with etodolac treatment intervals < 6 months prior to the onset of KCS were 4.2 times as likely to have remission as were dogs with treatment intervals ≥ 6 months.

Conclusions and Clinical Relevance—Shorter duration of etodolac administration (< 6 months) was associated with improved outcome in 1 population of dogs. Monitoring of tear production should be considered prior to and during administration of etodolac in dogs.

All Time Past Year Past 30 Days
Abstract Views 169 0 0
Full Text Views 1734 1503 122
PDF Downloads 285 145 11
Advertisement